|
|
Vaccine Detail
|
GM-K562 cell vaccine |
| Vaccine Information |
- Vaccine Name: GM-K562 cell vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: granulocyte macrophage-colony stimulating factor (GM-CSF) (NCT00301093; NCT00809250; NCT00442130; NCT00361296; NCIT_C52190)
- Immunization Route: subcutaneous injection
- Description: This is a cell-based vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. This vaccine may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth.(NCIT_C52190) A cultured cell line is genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from a patient. (NCT00809250) Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia. (NCT00301093) The vaccine can also be combined with stem cell transplantation. (NCT00442130) The vaccine may induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3) in patients with Myelodysplastic Syndrome. (NCT00361296)
|
| Host Response |
|
|
| References |
NCIT_C52190: GM-K562 Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C52190]
NCT00301093: Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia [https://clinicaltrials.gov/study/NCT00301093]
NCT00361296: Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes [https://clinicaltrials.gov/study/NCT00361296]
NCT00442130: Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination [https://clinicaltrials.gov/study/NCT00442130]
NCT00809250: Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation [https://clinicaltrials.gov/study/NCT00809250]
|
|
